Scarica l'app Stockscreener
2.55
2.82%
0.07
Dopo l'orario di chiusura:
2.55
Precedente Chiudi:
$2.48
Aprire:
$2.59
Volume 24 ore:
956.48K
Relative Volume:
0.59
Capitalizzazione di mercato:
$279.77M
Reddito:
-
Utile/perdita netta:
$-134.24M
Rapporto P/E:
-1.4407
EPS:
-1.77
Flusso di cassa netto:
$-121.34M
1 W Prestazione:
+8.97%
1M Prestazione:
+4.08%
6M Prestazione:
-38.26%
1 anno Prestazione:
-58.13%
Intervallo 1D:
$2.49
$2.6784
Intervallo di 1 settimana:
$2.2104
$2.6784
Portata 52W:
$1.285
$7.85
Annexon Inc Stock (ANNX) Company Profile
Nome
Annexon Inc
Settore
Industria
Telefono
(650)-822-5500
Indirizzo
1400 SIERRA POINT PARKWAY, BRISBANE
Confronta ANNX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
2.55 | 260.02M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Annexon Inc Stock (ANNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-12-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-30 | Iniziato | Wells Fargo | Overweight |
| 2023-05-26 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-05-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-09-16 | Iniziato | Jefferies | Buy |
| 2022-09-09 | Iniziato | BTIG Research | Buy |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-09-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-26 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Annexon Inc Borsa (ANNX) Ultime notizie
Annexon Inc. Stock Analysis and ForecastOutperformance with explosive growth - PrintWeekIndia
Annexon completes enrollment in phase 3 ARCHER II trial of vonaprument for geographic atrophy - Ophthalmology Times
Annexon completes enrollment for phase 3 dry AMD therapy trial - Investing.com Australia
Annexon, Inc. Completes Enrollment of Phase 3 ARCHER II Trial for Vonaprument, Targeting Vision Preservation in Dry AMD with Geographic Atrophy - Nasdaq
Annexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy - Yahoo Finance
What analysts say about Annexon Inc. stockBreakout portfolio performance - Autocar Professional
What drives Annexon Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Annexon Inc. a good long term investmentHigh-performance investment picks - Autocar Professional
Why Annexon Inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans? - 富途牛牛
Is Annexon Inc. stock a growth or value playHigh Reward Risk Balanced Trading - Newser
Annexon Inc (ANNX) Stock: A Comprehensive 52-Week Review - investchronicle.com
Annexon EVP Yednock sells $2.9k in shares By Investing.com - Investing.com South Africa
Annexon EVP Yednock sells $2.9k in shares - Investing.com Australia
What makes Annexon Inc. stock price move sharplyTop Performing Stocks - Newser
How Annexon Inc. stock performs during market volatilityWeekly Big Movers - Newser
Annexon: Lead GBS Therapy Stokes Near Term Potential (NASDAQ:ANNX) - Seeking Alpha
Annexon Target of Unusually Large Options Trading (NASDAQ:ANNX) - Defense World
Annexon (NASDAQ:ANNX) Stock Price Down 0.7% – Should You Sell? - Defense World
Annexon, Inc. shares rise 2.08% premarket after Apogee Therapeutics announces Phase 2 trial results. - AInvest
Annexon says enrollment of Phase 3 Archer II Trial expected to be completed in Q3 2025 - MarketScreener
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrop - GuruFocus
Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA) - GlobeNewswire
Bank of America Corp DE Sells 137,220 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc Azioni (ANNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):